[{"id":"56a60848-4dfa-45d9-a49c-7194c5f7a955","acronym":"","url":"https://clinicaltrials.gov/study/NCT06564623","created_at":"2025-02-25T15:09:15.826Z","updated_at":"2025-02-25T15:09:15.826Z","phase":"Phase 1","brief_title":"Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)","source_id_and_acronym":"NCT06564623","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Hiltonol (poly-ICLC)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-02-12"},{"id":"3fd4e005-f66e-41a9-982d-62459a2e84ea","acronym":"NCI-2018-01581","url":"https://clinicaltrials.gov/study/NCT03606967","created_at":"2021-01-18T17:43:57.034Z","updated_at":"2025-02-25T16:37:09.345Z","phase":"Phase 2","brief_title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03606967 - NCI-2018-01581","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab-actl) • Trodelvy (sacituzumab govitecan-hziy) • Hiltonol (poly-ICLC) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 04/13/2021","start_date":" 04/13/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-07"},{"id":"e678f6ac-527c-48a1-b805-9ef0c833b79e","acronym":"IRB00210915","url":"https://clinicaltrials.gov/study/NCT04117087","created_at":"2021-01-18T20:07:26.907Z","updated_at":"2025-02-25T14:28:43.898Z","phase":"Phase 1","brief_title":"Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer","source_id_and_acronym":"NCT04117087 - IRB00210915","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • CD8 • CD4","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 08/08/2025","primary_completion_date":" 08/08/2025","study_txt":" Completion: 08/08/2025","study_completion_date":" 08/08/2025","last_update_posted":"2025-02-03"},{"id":"22763cd5-04a0-4c19-8ce3-8bad45fab6c6","acronym":"CA209-8TX","url":"https://clinicaltrials.gov/study/NCT02960230","created_at":"2021-01-19T13:10:42.375Z","updated_at":"2025-02-25T14:36:49.894Z","phase":"Phase 1/2","brief_title":"H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas","source_id_and_acronym":"NCT02960230 - CA209-8TX","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02:01 • H3.3K27M • HLA-A*02 positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • H3.3K27M • HLA-A*02 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 11/18/2016","start_date":" 11/18/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-01-22"},{"id":"f04191d0-49ef-4557-a5c3-c47df0794683","acronym":"","url":"https://clinicaltrials.gov/study/NCT06782932","created_at":"2025-02-25T19:18:04.732Z","updated_at":"2025-02-25T19:18:04.732Z","phase":"Phase 1/2","brief_title":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","source_id_and_acronym":"NCT06782932","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • balstilimab (AGEN2034) • AGEN2373 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-20"},{"id":"b0a219e9-f08b-4dc8-9baf-aea7746f89fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02287428","created_at":"2021-01-18T10:46:55.814Z","updated_at":"2025-02-25T16:14:11.420Z","phase":"Phase 1","brief_title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","source_id_and_acronym":"NCT02287428","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • temozolomide • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-12-05"},{"id":"b6408f31-64ba-4552-abf1-9f1e08679263","acronym":"","url":"https://clinicaltrials.gov/study/NCT04201873","created_at":"2024-05-04T04:26:32.002Z","updated_at":"2025-02-25T16:09:44.966Z","phase":"Phase 1","brief_title":"Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma","source_id_and_acronym":"NCT04201873","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PD-L1 • CD8 • PD-1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/08/2020","start_date":" 01/08/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-10-16"},{"id":"5444acae-553a-425f-a15f-fcc1a2b42abb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02826434","created_at":"2021-01-18T13:51:30.016Z","updated_at":"2025-02-25T15:07:08.523Z","phase":"Phase 1","brief_title":"Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer","source_id_and_acronym":"NCT02826434","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-09-23"},{"id":"184b42cd-fc1a-41ec-835c-53a5e57b12cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04248569","created_at":"2021-01-18T20:38:55.389Z","updated_at":"2025-02-25T14:29:00.465Z","phase":"Phase 1","brief_title":"DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma","source_id_and_acronym":"NCT04248569","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD4 • DNAJB1 • PRKACA","pipe":" | ","alterations":" DNAJB1-PRKACA fusion","tags":["CD8 • CD4 • DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • DNAJB1-PRKACA peptide vaccine • Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/20/2020","start_date":" 04/20/2020","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-06-07"},{"id":"464500ff-e8fe-41f5-868c-2b492ff3e949","acronym":"GCC-16047","url":"https://clinicaltrials.gov/study/NCT02834052","created_at":"2021-01-18T13:54:28.786Z","updated_at":"2025-02-25T16:04:58.190Z","phase":"Phase 1/2","brief_title":"Pembrolizumab + Poly-ICLC in MRP Colon Cancer","source_id_and_acronym":"NCT02834052 - GCC-16047","lead_sponsor":"Asha Nayak","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 01/10/2018","start_date":" 01/10/2018","primary_txt":" Primary completion: 07/29/2022","primary_completion_date":" 07/29/2022","study_txt":" Completion: 07/29/2022","study_completion_date":" 07/29/2022","last_update_posted":"2024-06-07"},{"id":"419c5914-39f8-4485-aeac-7765e3d16495","acronym":"HAITEN-ICI","url":"https://clinicaltrials.gov/study/NCT06064279","created_at":"2023-10-03T19:11:18.305Z","updated_at":"2024-07-02T16:35:06.817Z","phase":"Phase 1/2","brief_title":"Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC","source_id_and_acronym":"NCT06064279 - HAITEN-ICI","lead_sponsor":"VA Office of Research and Development","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/24/2024","start_date":" 06/24/2024","primary_txt":" Primary completion: 06/22/2026","primary_completion_date":" 06/22/2026","study_txt":" Completion: 04/04/2028","study_completion_date":" 04/04/2028","last_update_posted":"2024-04-30"},{"id":"7737d144-a404-4582-aab1-5735a517fdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206047","created_at":"2021-01-18T15:48:08.496Z","updated_at":"2024-07-02T16:35:11.758Z","phase":"Phase 1/2","brief_title":"Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03206047","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CTAG1B","pipe":" | ","alterations":" PD-L1 expression • CTAG1B expression","tags":["PD-L1 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-03"},{"id":"6dcd86de-9151-4b21-9983-a57a1be5a9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05025488","created_at":"2021-08-27T12:53:08.421Z","updated_at":"2024-07-02T16:35:14.494Z","phase":"Phase 1","brief_title":"Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm","source_id_and_acronym":"NCT05025488","lead_sponsor":"Marina Kremyanskaya","biomarkers":" CALR","pipe":" | ","alterations":" CALR mutation","tags":["CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/04/2023","start_date":" 04/04/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-15"},{"id":"8f8e9487-9ee4-4fb4-9fb0-f22de3968e90","acronym":"NF111","url":"https://clinicaltrials.gov/study/NCT04544007","created_at":"2021-01-18T21:44:13.649Z","updated_at":"2024-07-02T16:35:14.441Z","phase":"Phase 2","brief_title":"A Phase II Trial of Poly-ICLC for Low-Grade Gliomas","source_id_and_acronym":"NCT04544007 - NF111","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/15/2021","start_date":" 12/15/2021","primary_txt":" Primary completion: 02/15/2026","primary_completion_date":" 02/15/2026","study_txt":" Completion: 02/15/2027","study_completion_date":" 02/15/2027","last_update_posted":"2024-03-15"},{"id":"3179b0f4-ea2a-4800-a780-ec771c8348bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06218303","created_at":"2024-01-23T18:20:49.964Z","updated_at":"2024-07-02T16:35:15.510Z","phase":"Phase 1","brief_title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","source_id_and_acronym":"NCT06218303","lead_sponsor":"Finn, Olivera, PhD","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/07/2024","start_date":" 02/07/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-03-08"},{"id":"39c6b350-3479-44ce-a2c9-487a64f9b6ef","acronym":"MEL60","url":"https://clinicaltrials.gov/study/NCT02126579","created_at":"2021-01-29T07:06:15.841Z","updated_at":"2024-07-02T16:35:17.147Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists","source_id_and_acronym":"NCT02126579 - MEL60","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" CD8 • IFNG","pipe":"","alterations":" ","tags":["CD8 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 11/20/2019","primary_completion_date":" 11/20/2019","study_txt":" Completion: 05/05/2021","study_completion_date":" 05/05/2021","last_update_posted":"2024-02-28"},{"id":"dbd8060f-f9fc-4e93-8baf-7895d90d342a","acronym":"Mel-65","url":"https://clinicaltrials.gov/study/NCT03617328","created_at":"2021-01-29T07:17:48.889Z","updated_at":"2024-07-02T16:35:20.701Z","phase":"Phase 1/2","brief_title":"Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma","source_id_and_acronym":"NCT03617328 - Mel-65","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e varlilumab (CDX 1127) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 01/19/2024","primary_completion_date":" 01/19/2024","study_txt":" Completion: 01/19/2024","study_completion_date":" 01/19/2024","last_update_posted":"2024-02-06"},{"id":"2a13790b-df30-4d16-94bd-4e9b80cce1c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05098210","created_at":"2021-10-28T17:56:20.511Z","updated_at":"2024-07-02T16:35:22.189Z","phase":"Phase 1","brief_title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer","source_id_and_acronym":"NCT05098210","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • BRAF • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • BRAF • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-25"},{"id":"e67b207c-524d-4340-9a2e-5cbef643f117","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616248","created_at":"2021-01-19T20:33:34.730Z","updated_at":"2024-07-02T16:35:26.987Z","phase":"Phase 1","brief_title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT04616248","lead_sponsor":"University of Southern California","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/09/2023","start_date":" 01/09/2023","primary_txt":" Primary completion: 01/09/2025","primary_completion_date":" 01/09/2025","study_txt":" Completion: 01/09/2026","study_completion_date":" 01/09/2026","last_update_posted":"2023-12-06"},{"id":"fd91fe18-af69-409c-a905-0f8aee67d795","acronym":"","url":"https://clinicaltrials.gov/study/NCT01130077","created_at":"2021-01-18T04:29:21.248Z","updated_at":"2024-07-02T16:35:30.493Z","phase":"Phase 1","brief_title":"A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas","source_id_and_acronym":"NCT01130077","lead_sponsor":"James Felker","biomarkers":" IFNG","pipe":" | ","alterations":" HLA-A2 positive","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-03"},{"id":"12fc1d17-0a06-4691-bf0b-18767b9a6e88","acronym":"Mel66","url":"https://clinicaltrials.gov/study/NCT04364230","created_at":"2021-01-18T21:05:35.842Z","updated_at":"2024-07-02T16:35:33.934Z","phase":"Phase 1/2","brief_title":"Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)","source_id_and_acronym":"NCT04364230 - Mel66","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" BRAF • CD4 • FOXP3","pipe":"","alterations":" ","tags":["BRAF • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-10-11"},{"id":"809a0473-89c4-4bc7-8faf-bd2441b7e0a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02549833","created_at":"2021-01-18T12:20:05.485Z","updated_at":"2024-07-02T16:35:34.594Z","phase":"Phase 1","brief_title":"Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma","source_id_and_acronym":"NCT02549833","lead_sponsor":"Jennie Taylor","biomarkers":" CD8 • CXCL10 • CD4","pipe":" | ","alterations":" CXCL10 expression","tags":["CD8 • CXCL10 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCL10 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GBM6-AD • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/17/2016","start_date":" 10/17/2016","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-10-05"},{"id":"d94de171-8220-41f2-8706-22ba38f8e320","acronym":"ETAPA I","url":"https://clinicaltrials.gov/study/NCT05283109","created_at":"2022-03-16T15:54:21.194Z","updated_at":"2024-07-02T16:35:37.647Z","phase":"Phase 1","brief_title":"ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM","source_id_and_acronym":"NCT05283109 - ETAPA I","lead_sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","biomarkers":" MGMT • BIRC5","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • P30-EPS"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/30/2023","start_date":" 08/30/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2023-09-08"},{"id":"fc21c219-c013-4138-9fe8-07a9c22cead0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013216","created_at":"2021-08-19T14:52:56.438Z","updated_at":"2024-07-02T16:35:38.156Z","phase":"Phase 1","brief_title":"Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer","source_id_and_acronym":"NCT05013216","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1","pipe":" | ","alterations":" KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation","tags":["KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-09-04"}]